analysts and calls -- Morgan Stanley Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : analysts and calls -- Morgan Stanley

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (24)	5/14/2003 6:21:51 PM
From: tuck	Read Replies (2) of 31

I suspect Harr's Velcade revenue assumptions are a) on the low end of the range) and b) based on a launch much later than next week. From CBS Marketwatch: >>Barry Greene, Millennium's general manager for oncology, said the company will start shipping Velcade next week. "This is a fabulous day for multiple myeloma patients because they now have a new treatment option for an incurable condition," Greene said. Millennium plans to charge about $20,000 per course of treatment with Velcade.<< snip >>Analyst Bill Tanner at Leerink Swann & Co. said the drug could have a revenue opportunity exceeding $200 million in 2004.<< That's a far cry from the $250 million within five years. Cited in the clip you referenced from two months ago. Perhaps Tanner is being irrationally exuberant (or is trying to get some banking business for his firm if MS doesn't want it). Well, enough. We'll see what Harr does next and judge him some more then. Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next